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Abstract: This study was designed to investigate the protective effect of the heart-protecting 
musk pill (HMP) on inflammatory injury of kidney from spontaneously hypertensive rat 
(SHR). Male SHRs aged 4 weeks were divided into SHR model group, HMP low-dosage 
group (13.5 mg/kg), and HMP high-dosage group (40 mg/kg). Age-matched Wistar–Kyoto 
rats were used as normal control. All rats were killed at 12 weeks of age. Tail-cuff method and 
enzyme-linked immunosorbent assay were used to determine rat systolic blood pressure and 
angiotensin II (Ang II) contents, respectively. Renal inflammatory damage was evaluated by the 
following parameters: protein expressions of inflammatory cytokines, carbonyl protein   contents, 
nitrite concentration, infiltration of monocytes/macrophages in interstitium and glomeruli, 
kidney pathological changes, and excretion rate of urinary protein. HMP did not prevent the 
development of hypertension in SHR. However, this Chinese medicinal compound decreased 
renal Ang II content. Consistent with the change of renal Ang II, all the parameters of renal 
inflammatory injury were significantly decreased by HMP. This study indicates that HMP is a 
potent suppressor of renal inflammatory damage in SHR, which may serve as a basis for the 
advanced preventive and therapeutic investigation of HMP in hypertensive nephropathy.
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Introduction
The kidney can be both a target of and a contributor to hypertension. Spontaneously 
hypertensive rats (SHRs) have been widely used as a primary hypertension animal 
model, and multiple renal structural and functional alterations mark the feature of 
hypertensive nephropathy. It has been revealed that a complex pathological network 
involving angiotensin II (Ang II), monocytes/macrophages, inflammatory cytokines, 
and oxidative stress is an important participant in triggering renal injury of SHR.1–3 
Thus, we hypothesize that anti-inflammatory therapeutic strategy may manage hyper-
tensive target organ damage, and previous studies of our research center has indicated 
anti-inflammation mechanism may serve as a base for the protective effects of ator-
vastatin in hypertensive nephropathy.4
Heart-protecting musk pill (HMP) is a traditional Chinese medicinal compound, 
which has been effectively used for treating coronary heart disease (CHD) with angina 
pectoris.5 Recently, there has been a new wave of interest in the HMP due to its protect-
ing effect on multiple organ injuries. HMP improves renal function and blood pressure 
when combined with other hypotensive agents in hypertensive patients.6 Post-treatment 
with HMP decreases myocardial fibrosis in SHR without interfering with systolic 
blood pressure (SBP).7 Furthermore, HMP reduces arterial inflammation markers of International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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C-reactive protein (CRP), fibrinogen, and D-dimer levels in 
coronary syndrome subjects.8 Little is known, however, about 
the mechanisms underlying these multiple organ protective 
effects of HMP.
The present study was designed to explore the effect 
of HMP on renal inflammatory parameters, pathological 
  morphology and functional changes in SHR. With this study, 
we expect to clarify the protective mechanisms and potential 
clinical benefits of HMP on hypertensive nephropathy.
Materials and methods
experimental animals
The animal procedures were in accordance with the Animal 
Use and Care Guidelines of the Experimental Animal Center 
of Shanghai University of Traditional Chinese Medicine. 
Male SHR (aged 4 weeks) and Wistar–Kyoto (WKY) rats 
(aged 4 weeks) were purchased from Shanghai   Experimental 
Animal Center of Chinese Academy of Sciences. All the 
rats were housed in a temperature-controlled room regu-
lated on a 12-hour light/dark cycle with free access to food 
and water.
Materials
HMP were purchased from Shanghai Hutchison Pharmaceuti-
cals (Shanghai, China). An instrument for noninvasive blood 
pressure determination was purchased from Shanghai Alcott 
Biotech (Shanghai, China). Commercially available Ang II, 
monocyte chemotactic protein (MCP)-1, and microalbuminu-
ria (MA), enzyme-linked immunosorbent assay (ELISA) kits 
were obtained from BioDev Tech (Beijing, China). JD801 
analysis system for pathological image was purchased from 
Jiangsu Jieda Biotech (Jiangsu, China). Primary antibodies of 
inductible nitric oxide synthase (iNOS) (sc-8310), intercel-
lular adhesion molecule (ICAM)-1 (sc-1511), transforming 
growth factor (TGF)-β1 (sc-146), and β-actin (sc-47778) 
were obtained from Santa Cruz Biotechnology Inc (Santa 
Cruz, CA). A computerized gel imaging analysis system 
was obtained from Shanghai Tannon (Shanghai, China). 
A radio immunoassay kit of β2-microglobulin (β2-MG) was 
purchased from Beijing North Institute Biotech (Beijing, 
China). Multifunctional microplate reader Spectra Max 
190 was obtained from Molecular Devices (Carlsbad, CA). 
All chemicals were of analytical grade.
experimental groups and treatment
SHR were divided into three experimental groups: SHR 
model group (n = 9), HMP low dosage group (13.5 mg/kg, 
n = 9), and HMP high dosage group (40 mg/kg, n = 9). 
HMP powder was dissolved in purified water (HMP low 
dosage, 1.35 mg/mL; HMP high dosage, 4.0 mg/mL), and 
daily administrated through intragastric gavage (10 mL/kg). 
Drinking water (10 mL/kg) was used for the SHR model 
group. The treatments were carried out through week 4 
to week 12 of the age of SHR. In the whole experimental 
process WKY rats (n = 9) were used as the age-matched 
control of SHR, and drinking water (10 mL/kg) was used 
for sham treatment.
sample preparation
Pelltobarbitalum natricum (40 mg/kg) was used for the anes-
thesia of rats. Twenty-four hour urine samples were collected 
on the day before rats were killed by cervical dislocation. 
Urine samples were lower-speed centrifuged, and superna-
tants were separated and stored at −20°C until assayed for 
urinary concentrations of total protein, MA, and β2-MG.
Blood samples were obtained at 12 weeks of age through 
cardiac puncture and collected in centrifuge tubes that 
contained 50 µL EDTA (0.30 mol/L), 25 µL dimercaprol 
(0.32 mol/L) and 50 µL 8-hydroxyquinoline sulfate 
(0.34 mol/L). Plasma was separated and stored at −20°C for 
further assays.
Kidneys were immediately removed after sacrifice of 
the rats. One kidney was fixed with 4% paraformaldehyde 
for histological analysis, and another kidney was frozen in 
liquid nitrogen for protein assays and preparation of renal 
tissue homogenates.
sBP measurement
SBP was measured weekly by using tail-cuff method. The 
cuff was inflated until the pulse waveform disappeared; values 
at the disappearance of the waveform was recorded as the 
systolic pressure.
Plasma and kidney Ang II determination
Ang II concentration was detected using ELISA kit according 
to the manufacturer’s instructions.
Examination of renal inflammatory injury
ICAM-1, iNOS, and TGF-β1 protein expression was ana-
lyzed by Western-blot. For total protein extraction, about 
200 mg kidney tissues were homogenized in cell lysis buffer 
(pH 7.4) containing proteinase inhibitors and centrifuged for 
15   minutes at 4 g. Concentration of total protein was deter-
mined by Lowry assay. A total of 50 µg protein was separated 
in sodium dodecyl sulfate polyacrylamide gel electrophore-
sis (SDS-PAGE), protein was transferred to nitrocellulose International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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  membrane, and then incubated with primary antibodies 
(1:200) overnight and second antibodies conjugated with 
horseradish peroxidase for 1 hour. The determination was 
performed with enhanced chemiluminescene by exposure to 
X-Omat BT Films (Kodak, Rochester, NY).
Kidney protein level of MCP-1 was determined using 
commercially available ELISA kit. Carbonyl protein for-
mation was determined by 2, 4-dinitrophenylhydrazine 
(DNPH) method.9 The results were calculated using the 
extinction coefficient of 22,000 for aliphatic hydrazone and 
  demonstrated by nmol/mg protein.
Griess reaction was used for the detection of renal tissue 
nitrite (NO2
−) concentration. Test solutions (100 µL) were 
added to 96-well flat-bottomed plates containing 100 µL/well 
of Griess reagent (1% sulfanilamide, 0.1% naphtylethylene-
diamine dihydrochloride, and 5% phosphoric acid). After 
10 minutes at room temperature the absorbance of each well 
was measured at 540 nm, and the NO2
− concentration was 
determined from a sodium nitrite standard curve.
Infiltration of monocytes/macrophages was examined by 
immunochemistry using CD68 antibody. Images of immuno-
chemistry were counterstained with hematoxylin and eosin 
(HE). Fifteen consecutive microscopic fields were examined 
for each kidney section, and CD68-positive cells (brown) 
were counted in interstitium and glomeruli.
With the use of HE and periodic acid silver metheramine 
(PASM) stained kidney sections, pathological morpho-
logic changes were evaluated by using a semi-quantitative 
histological score (score 0–3; normal to severe) for glom-
erulosclerosis, interstitial fibrosis, tubular atrophy, and 
arteriolar hyalinosis (maximal score = 12) as described 
previously.10
Renal function was evaluated by urinary excretion 
rates of total protein, β2-MG, and MA. Urinary concentra-
tion of total protein was measured by Coomassie Brilliant 
Blue method. ELISA and radioimmunoassay (RIA) kits 
were used for the determination of MA and β2-MG levels, 
respectively.
statistical analysis
The experimental data were expressed as mean ± standard 
deviation (SD). Results were analyzed by Student’s t-test, 
and a P value of less than 0.05 was considered statistically 
significant.
Results
sBP
SHR showed a progressive increase in SBP during the 
whole experimental period, whereas WKY rats maintained 
their SBP unchanged (P . 0.05). HMP treatment failed to 
prevent the development of hypertension in SHR (P . 0.05) 
(Table 1).
Plasma and kidney Ang II
Plasma Ang II concentrations were similar between WKY 
rats and SHR at 12 weeks of age (P . 0.05). HMP low dos-
age treatment showed a tendency to decrease plasma Ang II 
levels in SHR group. However, these changes were not sta-
tistically significant (P . 0.05). HMP high dosage prevented 
this increase in plasma Ang II (P , 0.01). In contrast, kidney 
tissue levels of Ang II were significantly increased in SHR 
at 12 weeks of age compared with age-matched WKY rats 
(P , 0.05). After 8 weeks of treatment, kidney Ang II levels 
were markedly decreased by HMP (P , 0.05) (Table 1).
renal protein expressions of inOs, 
IcAM-1, and TGF-β1
Renal protein expressions of iNOS, ICAM-1, and TGF-β1 
were significantly increased in SHR at 12 weeks of age com-
pared with age-matched WKY rats (P , 0.05 or P , 0.01). 
HMP treatment prevented the increased protein expressions 
of iNOS, ICAM-1, and TGF-β1 in SHR kidney (P , 0.05 or 
P , 0.01) (Figures 1A, 1B, and 1C).
renal protein levels of McP-1
Renal protein levels of MCP-1 were significantly increased in SHR 
at 12 weeks of age (37.40 ± 7.48 pg/mg renal tissue) compared 
Table 1 effect of hMP on sBP and Ang II levels of shr
Group SBP (mm Hg) Ang II
4 weeks of age 12 weeks of age Plasma (pg/mL) Kidney (pg/mg tissue)
WKY rats 132.3 ± 7.45 138.5 ± 10.62 435.2 ± 154.8 18.09 ± 7.92
shr 131.8 ± 5.90 193.3 ± 5.72a 474.9 ± 96.9 30.70 ± 10.94b
hMP low dosage 135.3 ± 8.90 194.0 ± 9.09 390.6 ± 130.4 24.44 ± 8.60c
hMP high dosage 134.0 ± 8.04 196.8 ± 9.87 196.6 ± 35.9d 21.16 ± 6.03c
Notes: Values are expressed in mean ± standard deviation (n = 9). Statistical significant test for comparison was done by one-way ANOVA. aP , 0.01, versus WKY rats 
(shr only); bP , 0.05, versus WKY rats (shr only); cP , 0.05, versus shr; dP , 0.01, versus shr.
Abbreviations: Ang II, angiotensin II; hMP, heart-protecting musk pill; sBP, systolic blood pressure; shr, spontaneously hypertensive rats; WKY, Wistar Kyoto.International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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Figure 1 Effect of HMP on protein expressions of inflammatory cytokines in SHR kidney. Total protein was extracted from kidney for Western-blot assay to determine 
inOs, IcAM-1, and TGF-β1 protein expression. Optical density of bands corresponding to Western-blot were read by gel imaging analysis system, and optical density of 
each band was expressed as the percentage relative to the corresponding β-actin band (%). renal tissue homogenates and eLIsA kits were used for the examination of 
McP-1 protein level. Data of McP-1 protein level were calculated from the standard curve plotted according to the manufacturer’s instructions. A) Bands corresponding 
to Western-blot. B) Bar graph of inOs. C) Bar graph of IcAM-1. D) Bar graph of TGF-β1. E) Bar graph of McP-1. renal tissue homogenates and eLIsA kits were used for 
the examination of McP-1 protein level.
Notes: #P , 0.05, ##P , 0.01 versus WKY rats (shr only); *P , 0.05, **P , 0.01 versus shr, n $ 3 (Westein-blot) or n = 9 (eLIsA).
Abbreviations: eLIsA, enzyme linked immunosorbent assay; hMP, heart-protecting musk pill; IcAM, intercellular adhesion molecule; inOs, inductible nitric oxide synthase; 
McP, monocyte chemotactic protein; shr, spontaneously hypertensive rat; TGF, transforming growth factor; WKY, Wistar Kyoto.International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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with age-matched WKY rats (24.05 ± 6.28 pg/mg renal tissue) 
(P , 0.05). HMP decreased renal protein levels of MCP-1 in SHR 
significantly after 8 weeks of treatment (29.73 ± 7.32 pg/mg renal 
tissue for HMP low dosage group; 25.77 ± 4.96 pg/mg renal tissue 
for HMP high dosage group) (P , 0.05) (Figure 1D).
renal carbonyl protein and nO2
− 
contents
Compared with WKY rats, renal carbonyl protein and 
NO2
− contents in SHR changed in parallel with protein 
expressions of inflammatory cytokines. HMP decreased con-
tents of carbonyl protein and NO2
− after 8 weeks of   treatment 
(P , 0.05 or P , 0.01) (Table 2).
Infiltration of monocytes/macrophages
Numbers of monocytes/macrophages in interstitium and 
glomeruli were significantly increased in SHR at 12 weeks 
of age compared with age-matched WKY rats (P , 0.05 or 
P , 0.01, respectively). HMP inhibited the renal cortical 
infiltration of monocytes/macrophages in SHR (P , 0.05 
or P , 0.01) (Figure 2 and Table 2).
renal pathological parameters
Pathological scores of glomeruli, tubule-interstitum, and 
renal vascular lesions were significantly increased in SHR 
at 12 weeks of age compared with age-matched WKY rats 
(P , 0.05 or P , 0.01). After 8 weeks of treatment, HMP 
significantly decreased the pathological scores of glom-
eruli, tubule-interstitum, and renal vascular lesions in SHR 
(P , 0.05 or P , 0.01) (Figure 3; Table 3).
Urinary excretions of total protein, MA, 
and β2-MG
Urinary excretions of total protein, MA, and β2-MG were 
significantly increased in SHR at 12 weeks of age compared 
with age-matched WKY rats (P , 0.01). After 8 weeks of HMP 
treatment, urinary excretions of total protein, MA, and β2-MG 
were markedly decreased (P , 0.05 or P , 0.01) (Table 4).
Discussion
The pathological changes due to chronic inflammation are 
evidential in hypertensive renal disease. Interstitial fibrosis, 
proteinuria, and decreased creatinine clearance rate manifest 
severe renal disorders of SHR. Our previous studies indi-
cated the up-regulated inflammatory cytokines expression 
was present in SHR kidney, and the protective effects of 
atorvastatin in hypertensive nephropathy might be related to 
its anti-inflammation mechanism.2–4 A role of inflammatory 
reaction in hypertensive nephropathy is further suggested 
by the study of nuclear transcription factor-κB (NF-κB) 
  inhibitor, which prevented the development of hypertension 
and renal injury.11 To add more evidence, chronic treatment 
with p38 MAPK inhibitor delayed the onset of renal dysfunc-
tion characterized by increased total protein and albumin 
excretion of SHR.12 In the present study, we have evaluated 
the effect of HMP on inflammation-related kidney damage 
in SHR to appeal our proposed concept that inflammation 
serves as primary target of therapeutic strategy in end-organ 
damage of hypertension. Our choosing of HMP is due to the 
following considerations: 1) HMP is not an anti-hypertensive 
drug, 2) HMP exerts   cardiovascular effect through anti-
inflammatory mechanisms, and 3) HMP is the top-selling 
prescription medicine in China and available immediately 
for therapeutic use.
It is widely accepted that elevated BP positively correlates 
to hypertensive target organ damage, including renal injury. 
However, it has been reported that atorvastatin reduced pro-
teinuria and decreased CRP and IL-6 in renal damage patients 
of hypertension without interfering with BP.13 In contrast, 
hydrochlorothiazide (HRH) treatment failed to prevent the 
increase of renal injury in SHR, even though HRH effectively 
blocked the development of hypertension.14 These studies 
Table 2 effect of hMP on renal carbonyl protein and nO2
− contents, and monocytes/macrophages infiltration of SHR
Group Carbonyl protein 
(nmol/mg protein)
NO2
− (μmol/g) Monocytes/macrophages
Glo (count/glo) Interstitium 
(count/mm2)
WKY rats  2.81 ± 0.99 0.44 ± 0.08 10.1 ± 3.3 23.1 ± 4.7
shr 5.15 ± 1.70a 0.63 ± 0.85b 24.5 ± 6.3a 38.9 ± 6.2b
hMP low dosage 2.43 ± 1.29c 0.45 ± 0.06c 13.4 ± 5.5c 23.6 ± 3.4c
hMP high dosage 1.25 ± 0.96d 0.45 ± 0.08c 10.8 ± 3.6d 21.6 ± 4.2c
Notes: Values are expressed in mean ± standard deviation (n = 6). Statistical significant test for comparison was done by one-way ANOVA. 
aP , 0.01, versus WKY rats (shr only); bP , 0.05, versus WKY rats (shr only); cP , 0.05 versus shr; dP , 0.01 versus shr.
Abbreviations: Glo, glomeruli; hMP, heart-protecting musk pill; shr, spontaneously hypertensive rats; nO2
−, nitrite; WKY, Wistar Kyoto.International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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suggested that, under certain conditions, BP elevation and 
renal injury might stand for two independent pathological 
procedures. In this study we observed that HMP treatment 
failed to prevent the development of hypertension in SHR. 
On the other side, our data here are especially aimed to define 
the optimal treatment of hypertensive nephropathy through 
an anti-inflammation pathway.
Previous studies indicated a complex causative network 
involving Ang II and inflammatory cytokines in triggering 
renal damage in hypertension such as increasing mesangial 
cell proliferation, contracting afferent and efferent glomerular 
arteriole, and decreasing glomerular filtration rate.15 Also, 
it has been reported that Ang II stimulated the synthesis of 
type I and type IV collagen and fibronectin,16 thus increas-
ing the extracellular matrix (ECM) deposition. On the other 
side, olmesartan, an Ang II type-1 (AT1) receptor blocker, 
decreased proteinuria, renal immune cells infiltration and 
morphology alterations in SHR by inhibition of kidney 
levels of Ang II.17 In this study, we observed the similar 
result that HMP inhibited levels of Ang II which implied a 
key role of Ang II in regulation of chronic inflammation in 
hypertension.
Inflammatory cytokines have been crucially involved in 
the pathogenesis of hypertensive renal damage. Our current 
study focused on the effect of HMP on iNOS, ICAM-1, 
TGF-β1, and MCP-1 protein expressions in SHR kidney. The 
production of pathological higher concentration of nitric oxide 
(NO) by iNOS has been considered as a pro-  inflammatory 
mediator and implicated in several cardiovascular   diseases.18 
Inflammatory cytokines,   including interleukin (IL)-1β, 
tumor necrosis factor (TNF)-α, interferon (IFN)-γ, and 
bacterial lipopolysaccharide can induce the expression of 
iNOS in monocytes/macrophages, neutrophil granulocytes, 
and many other cell types. The overproduced NO will react 
with superoxide anion to form peroxynitrite (ONOO−), 
which can react with tyrosine residue to form nitrotyrosin 
Figure 2 Effect of HMP on monocytes/macrophages stained positively with CD68 antibody in SHR interstitial (A–D) and glomerular (E–H). Immunochemistry staining, 
original magnification ×400). A and E refer to WKY rats; B and F refer to shr; C and G refer to hMP low dosage group; D and H refer to hMP high dosage group. 
Abbreviations: hMP, heart-protecting musk pill; shr, spontaneously hypertensive rat; WKY, Wistar Kyoto.International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
137
hypertensive nephropathy treatment by heart-protecting musk pill
and cause tissue injury, including renal damage.9 In the 
current study, renal tissue NO2
− concentration evaluated 
as the consequence of over expressed iNOS was inhibited 
by HMP treatment. Upregulation of ICAM-1 in tubular 
epithelial cells observed in kidney diseases with inflam-
mation actively participated in the progress of fibrosis in 
glomeruli and tubule   interstitum.19 This study indicated that 
the ICMA-1 expression was significantly inhibited by HMP 
and suggested an action mechanism of HMP in preserving 
renal function and reducing interstitial fibrosis. TGF-β1 plays 
a key role in promoting the   overproduction of ECM and thus 
participates in renal structural and functional alterations.20 
MCP-1 exhibits a chemotactic activity toward monocytes/
macrophages and induces the production of inflammatory 
cytokines including TNF-α and IFN-γ, which have been 
shown to mediate pathological adhesion, migration, and 
phagocytosis of inflammatory cells.21,22 In addition, mac-
rophages stimulate renal interstitial fibrosis via the production 
Figure 3 effect of hMP on renal pathological parameters with the use of he (A–D) and PAsM (E–H) stained kidney sections in shr. A and E refer to WKY rats; B and F 
refer to shr; C and G refer to hMP low dosage group; D and H refer to hMP high dosage group.
Abbreviations: he, hematoxylin-erosin; hMP, heart-protecting musk pill; PAsM, periodic acid silver metheramine; shr, spontaneously hypertensive rat; WKY, Wistar Kyoto.
Table 3 effect of hMP on renal pathological parameters in shr kidney
Group Pathological scores
Glomeruli Tubule-interstitium Vascular Total
WKY rats 1.08 ± 0.49 1.58 ± 0.66 1.08 ± 0.38 3.57 ± 1.03
shr 5.17 ± 1.66a 5.25 ± 1.83b 3.50 ± 1.05a 13.9 ± 4.30b
hMP low dosage 2.42 ± 1.24c 3.17 ± 1.03c 1.92 ± 1.07c 7.50 ± 1.87c
hMP high dosage 1.83 ± 0.82d 2.58 ± 1.11c 1.83 ± 0.82d 6.25 ± 1.63c
Notes: Values are expressed in mean ± standard deviation (n = 6). Statistical significant test for comparison was done by one-way ANOVA. 
aP , 0.01, versus WKY rats (shr only); bP , 0.05, versus WKY rats (shr only); cP , 0.05, versus shr; dP , 0.01, versus shr.
Abbreviations: hMP, heart-protecting musk pill; shr, spontaneously hypertensive rats; WKY, Wistar Kyoto.International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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of matrix protein from renal interstitium and intercapillary 
cells.23 Thus, an agent that reduces monocytes/macrophages 
infiltration may be beneficial to hypertension-related renal 
fibrosis. In the present study, HMP decreased renal iNOS, 
ICAM-1, TGF-β1, and MCP-1 protein expressions, as well 
as interstitial and glomerular infiltration of monocytes/
macrophages, which implied the protective role of HMP in 
hypertensive nephropathy.
Inflammation is closely related to oxidative stress. The 
overproduction of reactive oxygen species (ROS) participate 
cellular and tissue damage through oxidative modification of 
protein, lipids, carbohydrate, and DNA.24 ROS can initiate 
local inflammation and tissue fibrosis by the activation of 
NF-κB and TGF-β signaling pathways, respectively.25,26 In this 
study, protein carbonyl content was evaluated as the parameter 
of oxidative stress. Our data showed that HMP decreased 
carbonyl protein levels in SHR kidney, which suggested an 
antioxidative mechanism might underlie the preventive and 
therapeutic effect of HMP on hypertensive renal injury.
Previous studies have detected renal pathological changes 
in SHR at 14 weeks of age, including: 1) accumulation 
of mesangial matrix and thickening and focal sclerosis 
of capillary basement membrane; 2) cloudy swelling and 
irregular basement membrane thickening of renal tubules; and 
3)   interstitial inflammatory cell infiltration, accumulation of 
ECM and fibrosis.14 In this study we got a similar result that the 
pathological scores of glomeruli, tubule interstitum, and renal 
vascular lesions were significantly increased in SHR at the 
age of 12 weeks. The reducing effect of HMP on pathological 
scores of SHR kidney strongly demonstrated the efficacy of 
anti-inflammation therapy on hypertensive renal injury.
Hypertensive nephropathy marks with increased excretion 
of urinary protein, which is mostly attributed to increased 
permeability of glomerular filtration membrane, damage of 
electrostatic barrier, and renal tubular reabsorption. Urinary 
excretions of albumin and β2-MG are sensitive to early func-
tional damage of glomerular filtration and renal tubular reab-
sorption, respectively. Albumin is a macromolecule carrying 
negative electric charges. Therefore, a small amount of albumin 
will penetrate through the glomerular electrostatic barrier 
under normal conditions. The urinary albumin concentration 
will be obviously increased even if there is a mild injury of 
electrostatic barrier.27,28 β2-MG can penetrate through the 
glomerular electrostatic barrier, and 99.9% of β2-MG will 
be reabsorbed by the proximal renal tubule. When the func-
tion of renal tubular reabsorption is damaged, urinary β2-MG 
concentration will be increased.28 The improvement of renal 
function (measured by urinary excretions of total protein, 
MA, and β2-MG) by HMP   further prove our concept of anti-
inflammatory therapy for   hypertensive target organ damage.
In conclusion, this study demonstrates that HMP inhibited 
inflammatory status of the hypertensive kidney which was 
associated with a marked improvement of kidney function 
in SHR. It is worth noting that the protective effect of HMP 
on hypertensive renal diseases is not related to the change of 
blood pressure. We propose the anti-inflammatory mecha-
nism may serve the base for the therapeutic investigation of 
HMP in hypertensive nephropathy.
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